Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: The PROMOTION Registry

Health and Quality of Life Outcomes

Volumn 12, Issue 1, 2014, Pages

  Efficace, Fabio ^a   Rees, Jonathan ^b   Fayers, Peter ^c   Pusic, Andrea ^d   Taphoorn, Martin ^e,g   Greimel, Elfriede ^f   Reijneveld, Jaap ^e   Whale, Katie ^b   Blazeby, Jane ^b  

^a Data Center and Health Outcomes Research Unit   (Italy)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

Cancer; Clinical decision making; Clinical trials; Patient reported outcomes; Quality of life

Indexed keywords

CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NOTE; OUTCOME ASSESSMENT; PATIENT INFORMATION; PHYSICIAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; PROGRAM DEVELOPMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; TREATMENT OUTCOME;

EID: 84904722021     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-12-86     Document Type: Note

References (21)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F, GLOBOCAN 2012 v1.0 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013, Lyon, France: International Agency for Research on Cancer, GLOBOCAN 2012 v1.0.
2. Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 2012, 9:98-109.
3. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Dobrez DG, Hensley ML, Cella D. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003, 21:2138-2146. 10.1200/JCO.2003.12.154, 12775739.
4. Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Barate C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F, GIMEMA Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011, 118:4554-4560. 10.1182/blood-2011-04-347575, 21750313, GIMEMA.
5. Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, Frank ES, Lipscomb J, Raymond SA, Spencer M, Tunis S. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012, 30:4249-4255. 10.1200/JCO.2012.42.5967, 23071244.
6. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999, 17:1654-1663.
7. Johnson JR, Williams G, Pazdur R. End points and united states food and drug administration approval of oncology drugs. J Clin Oncol 2003, 21:1404-1411. 10.1200/JCO.2003.08.072, 12663734.
8. Calvert M, Brundage M, Jacobsen PB, Schunemann HJ, Efficace F. The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes 2013, 11:184. 10.1186/1477-7525-11-184, 3842645, 24168680.
9. Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R. Quality of life assessment in clinical trials-guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office. Eur J Cancer 1997, 33:20-28. 10.1016/S0959-8049(96)00412-1, 9071894.
10. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: the example of health-related quality of life - a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002, 36:209-238.
11. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe P, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376. 10.1093/jnci/85.5.365, 8433390.
12. Bottomley A, Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol 2002, 3:620-628. 10.1016/S1470-2045(02)00876-8, 12372724.
13. Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH. Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol 2003, 21:2982-2992. 10.1200/JCO.2003.01.203, 12885819.
14. Efficace F, Bottomley A, Vanvoorden V, Blazeby JM. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 2004, 40:187-197. 10.1016/j.ejca.2003.10.012, 14728932.
15. Efficace F, Bottomley A, van Andel G. Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer 2003, 97:377-388. 10.1002/cncr.11065, 12518362.
16. Bottomley A, Efficace F, Fayers PM. Standards are needed for quality of life clinical trials. BMJ 2002, 324:1156. 10.1136/bmj.324.7346.1156, 1123109, 12003899.
17. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'Haese S, Zurlo A. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 2003, 21:3502-3511. 10.1200/JCO.2003.12.121, 12972527.
18. Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, Efficace F, King M, Lam CL, Moher D, Scott J, Sloan J, Snyder C, Yount S, Calvert M. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 2013, 22:1161-1175. 10.1007/s11136-012-0252-1, 3731511, 22987144.
19. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013, 309:814-822. 10.1001/jama.2013.879, 23443445.
20. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group; Cochrane Statistical Methods Group The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928. 10.1136/bmj.d5928, 3196245, 22008217, Cochrane Bias Methods Group; Cochrane Statistical Methods Group.
21. Efficace F, Feuerstein M, Fayers P, Cafaro V, Eastham J, Pusic A, Blazeby J. Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making. Eur Urol 2013, doi:10.1016/j.eururo.2013.10.017. [Epub ahead of print].